Innovent Biologics, Inc.
1801
株式のランク
#1152
Innovent Biologics, Inc., established in 2011 and headquartered in Suzhou,... Innovent Biologics, Inc., established in 2011 and headquartered in Suzhou, People's Republic of China, functions as a leading biopharmaceutical enterprise. The company is dedicated to the comprehensive lifecycle of antibody drug candidates, encompassing their discovery, development, and eventual manufacturing. Its therapeutic focus spans critical areas such as oncology, ophthalmology, immunology, and metabolic diseases. A key product in its portfolio is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody utilized in the treatment of various cancers, including Hodgkin's lymphoma and esophageal carcinoma. Innovent's commercialized offerings also include Byvasda, employed for several malignant tumors; Halpryza, which addresses non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and Wegener's granulomatosis; Pemazyre, indicated for adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib, designed for adult patients facing conditions related to tyrosine kinase inhibitors; and Cyramza, approved for four distinct cancer types. The company's robust pipeline features a range of investigational therapies, such as IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein aimed at ocular fundus disease; IBI-306, a human monoclonal antibody targeting hypercholesterolemia; and IBI-310, a recombinant human anti-CTLA-4 monoclonal antibody for liver and renal cell carcinoma. Further developmental assets include IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for adults with relapsed or refractory multiple myeloma; IBI-376 for recurrent or refractory follicular lymphoma; and IBI-112 for psoriasis. Beyond drug creation, Innovent Biologics is also involved in distributing pharmaceutical products and provides expert consultation along with research and development services. The company maintains key strategic alliances with various partners, including NeoCura Bio-Medical Technology Co. Ltd., Roche Group, Ascentage Pharma Group International, Eli Lilly and Company, and Bolt Biotherapeutics, Inc.
株価
$11.35
時価総額
$19.80B
変化（1日）
1.56%
変化（1年）
1.55%
国
CN
取引 Innovent Biologics, Inc. (1801)
カテゴリー
Healthcare
Innovent Biologics, Inc.（1801）の収益
Jun 2026 時点の収益 TTM: $2.26B
Innovent Biologics, Inc. の最新の財務報告によると、現在の収益 (TTM) は $2.26B です。2023 年には $876.74M の収益があり、これは 2022 年の $660.55M と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Innovent Biologics, Inc. の収益履歴（2016 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $2.26B | 74.99% |
| 2024 | $1.29B | 47.23% |
| 2023 | $876.74M | 32.73% |
| 2022 | $660.55M | -1.67% |
| 2021 | $671.77M | 14.17% |
| 2020 | $588.40M | 291.13% |
| 2019 | $150.44M | 10,818.89% |
| 2018 | $1.38M | -51.65% |
| 2017 | $2.85M | -38.42% |
| 2016 | $4.63M | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $12.62B | 458.89% |
US
|
|
| $2.23B | -1.36% |
US
|
|
| $15.74B | 597.02% |
AU
|
|
| $6.02B | 166.57% |
NL
|
|
| - | - |
CH
|
